Results 211 to 220 of about 967,148 (255)

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito   +8 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Electroclinical characterization and classification of symptomatic epilepsies with very early onset by multiple correspondence analysis

Epilepsy Research, 2010
To characterize very early onset symptomatic epilepsies electroclinically, to identify meaningful factors to delineate epilepsy syndromes under this category, and to test validity of the current syndromic organization of these epilepsies by the International League Against Epilepsy (ILAE).Subjects were 38 epileptic patients with seizure onset before 3 ...
Tomoyuki Akiyama
exaly   +3 more sources

Home - About - Disclaimer - Privacy